Company Filing History:
1 out of 1 
1 out of 9 
1 out of 3,100 
Years Active: 2021-2023
Title: Innovations of Xuxing Chen in Pharmaceutical Chemistry
Introduction
Xuxing Chen is a notable inventor based in Shanghai, China. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds with potential therapeutic applications. With a total of 2 patents, his work focuses on innovative solutions for treating tumors and autoimmune diseases.
Latest Patents
Xuxing Chen's latest patents include two groundbreaking inventions. The first patent is for indolizine compounds, which are represented by a specific formula and include a preparation method and their use. This indolizine compound exhibits an inhibitory effect on both wild-type and mutant EZH2 or EZH1, indicating its potential as a novel drug for anti-tumor therapies and the treatment of autoimmune diseases. The second patent involves a pyrido five-element aromatic ring compound, which also includes a preparation method and its use. Similar to the first, this compound has shown an inhibitory effect on wild-type and mutant EZH2, positioning it as a promising candidate for anti-tumor drugs and treatments for autoimmune conditions.
Career Highlights
Throughout his career, Xuxing Chen has worked with several prominent companies in the pharmaceutical industry. Notably, he has been associated with Haihe Biopharma Co., Ltd. and Shanghai Haihe Pharmaceutical Co., Ltd. His experience in these organizations has contributed to his expertise in drug development and innovation.
Collaborations
Xuxing Chen has collaborated with talented individuals in his field, including Yi Chen and Meiyu Geng. These collaborations have likely enhanced his research and development efforts, leading to the successful creation of his patented compounds.
Conclusion
Xuxing Chen's contributions to pharmaceutical chemistry through his innovative patents highlight his role as a significant inventor in the industry. His work on indolizine and pyrido compounds demonstrates the potential for new treatments in oncology and autoimmune diseases.